Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial
2005; Mary Ann Liebert, Inc.; Volume: 16; Issue: 9 Linguagem: Inglês
10.1089/hum.2005.16.1014
ISSN1557-7422
Autores Tópico(s)Cancer Research and Treatments
ResumoHuman Gene TherapyVol. 16, No. 9 EditorialGendicine: The First Commercial Gene Therapy Product; Chinese Translation of EditorialJames M. WilsonJames M. WilsonPublished Online:8 Sep 2005https://doi.org/10.1089/hum.2005.16.1014AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail "Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial." , 16(9), pp. 1014–1015FiguresReferencesRelatedDetailsCited byCombination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages5 January 2023 | Cancer Cell International, Vol. 23, No. 1Gen- und "Anti"-Gentherapie in der Onkologie11 May 2022Animal Cell Culture: Basics and Applications8 March 2022Current strategies of virotherapy in clinical trials for cancer treatment23 April 2021 | Journal of Medical Virology, Vol. 93, No. 8The current landscape of nucleic acid therapeutics31 May 2021 | Nature Nanotechnology, Vol. 16, No. 6Gene Therapy for Mucopolysaccharidosis Type II—A Review of the Current Possibilities23 May 2021 | International Journal of Molecular Sciences, Vol. 22, No. 11Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in ChinaCurrent Gene Therapy, Vol. 20, No. 2The approved gene therapy drugs worldwide: from 1998 to 2019Biotechnology Advances, Vol. 40Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy2 May 2020 | Cancers, Vol. 12, No. 5Pharmacodynamic Evaluation: Gene Therapy7 July 2020Commercial aspects and market potential of novel delivery systems for bioactives and biological agentsPathophysiology of Cancer Cell DeathFree Radical Scavenging and Some Pharmaceutical Utilities of Nanoparticles in the Recent ScenarioCurrent Pharmaceutical Design, Vol. 25, No. 24Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders25 September 2019 | Frontiers in Genetics, Vol. 10Cell death pathologies: targeting death pathways and the immune system for cancer therapy19 December 2018 | Genes & Immunity, Vol. 20, No. 7An effective and biocompatible polyethylenimine based vaginal suppository for gene deliveryNanomedicine: Nanotechnology, Biology and Medicine, Vol. 20Clinical translation of gene medicine15 July 2019 | The Journal of Gene Medicine, Vol. 21, No. 7Pharmacodynamic Evaluation: Gene Therapy25 May 2019mRNA therapeutics deliver a hopeful messageNano Today, Vol. 23p53 and metabolism: from mechanism to therapeutics17 April 2018 | Oncotarget, Vol. 9, No. 34The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic Wei-Wei Zhang, Longjiang Li, Dinggang Li, Jiliang Liu, Xiuqin Li, Wei Li, Xiaolong Xu, Michael J. Zhang, Lois A. Chandler, Hong Lin, Aiguo Hu, Wei Xu, and Dominic Man-Kit Lam1 February 2018 | Human Gene Therapy, Vol. 29, No. 2Macromolecular Theory and Simulations, Vol. 27, No. 2Gene Therapy and Free Flaps for Therapeutic Reconstructive Surgery3 August 2018Gene Therapy: Use of Viruses as VectorsTranscription factors: Time to deliverJournal of Controlled Release, Vol. 269Gene Therapy: An Evolving StorySpliced: Boundary-work and the establishment of human gene therapy28 June 2017 | BioSocieties, Vol. 12, No. 2Radiotherapy in the age of cancer immunology: Current concepts and future developmentsCritical Reviews in Oncology/Hematology, Vol. 112Drug and Gene Delivery Materials and DevicesSynergistic effects of overexpression of BMP-2 and TGF-β3 on osteogenic differentiation of bone marrow mesenchymal stem cells22 November 2016 | Molecular Medicine Reports, Vol. 14, No. 6Gene Therapy: A Paradigm Shift in Dentistry10 November 2016 | Genes, Vol. 7, No. 11Viruses, Artificial Viruses and Virus‐Based Structures for Biomedical Applications27 April 2016 | Advanced Healthcare Materials, Vol. 5, No. 12CRISPR as a driving force: the Model T of biotechnology12 September 2016 | Monash Bioethics Review, Vol. 34, No. 2Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview Dongsheng Duan22 March 2016 | Human Gene Therapy Clinical Development, Vol. 27, No. 1One-pot synthesis of functional poly(amino ester sulfide)s and utility in delivering pDNA and siRNAPolymer, Vol. 72Nonviral gene delivery31 July 2015Gene Replacement Therapy for Genetic Hepatocellular Jaundice16 October 2014 | Clinical Reviews in Allergy & Immunology, Vol. 48, No. 2-3Long-term toxicity study of rAd5-hTERTC27 in SD rats and Cynomolgus monkeys by intravenous injectionRegulatory Toxicology and Pharmacology, Vol. 71, No. 2Adenovirus-Vector-Mediated Gene Delivery: Barriers and Chemical Vector Modifications13 January 2015Noncoding Oligonucleotides: The Belle of the Ball in Gene TherapyVirus-inspired mimics: self-assembly of dendritic lipopeptides into arginine-rich nanovectors for improving gene delivery1 January 2015 | Journal of Materials Chemistry B, Vol. 3, No. 35Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromoleculesEuropean Journal of Pharmaceutics and Biopharmaceutics, Vol. 88, No. 1Pathophysiology of Cancer Cell DeathGene therapy as a new treatment option for inherited monogenic diseasesEuropean Journal of Internal Medicine, Vol. 25, No. 1Gene therapy on the move17 September 2013 | EMBO Molecular Medicine, Vol. 5, No. 11Chroniques génomiques18 October 2013 | médecine/sciences, Vol. 29, No. 10History of gene therapyGene, Vol. 525, No. 2Trial watch27 October 2014 | OncoImmunology, Vol. 2, No. 6Trial watch27 October 2014 | OncoImmunology, Vol. 2, No. 4Nose as a Route for Drug Delivery27 June 2013The Effect of CXCR4 Overexpression on Mesenchymal Stem Cell Transplantation in Ischemic Stroke1 July 2012 | Cell Medicine, Vol. 4, No. 2Physicochemical characterization techniques for lipid based delivery systems for siRNAInternational Journal of Pharmaceutics, Vol. 427, No. 1Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection14 July 2011 | Gene Therapy, Vol. 19, No. 3Functional lipids and lipoplexes for improved gene deliveryBiochimie, Vol. 94, No. 1Gene Therapy for Rheumatoid ArthritisBioDrugs, Vol. 25, No. 6A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiformeWorld Journal of Experimental Medicine, Vol. 1, No. 1Nanoparticulate delivery systems for targeted delivery of nucleic acids to cells4 November 2010 | Nanotechnologies in Russia, Vol. 5, No. 9-10Nucleic acid therapeutics: concepts for targeted delivery to solid tumorsTherapeutic Delivery, Vol. 1, No. 1Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profilesThe Journal of Pathology, Vol. 220, No. 5Production and Purification of Adenovirus Vectors for Gene Therapy15 March 2010Cell transfection by DNA-lipid complexes — Lipoplexes7 January 2010 | Biochemistry (Moscow), Vol. 74, No. 12The feasibility of gene therapy in the treatment of head and neck cancer12 January 2009 | Head & Neck Oncology, Vol. 1, No. 1Not gene therapy, but genetic surgery—the right strategy to attack cancer8 October 2009 | Molecular Genetics, Microbiology and Virology, Vol. 24, No. 3Targeting p53 for enhanced radio- and chemo-sensitivity4 March 2009 | Apoptosis, Vol. 14, No. 4Gene TherapyPrenatal gene therapy for the early treatment of genetic disorders10 January 2014 | Expert Review of Obstetrics & Gynecology, Vol. 4, No. 1Current status of gene therapy for rheumatoid arthritis16 October 2008 | Current Rheumatology Reports, Vol. 10, No. 5Plastic Surgical Delivery Systems for Targeted Gene TherapyAnnals of Plastic Surgery, Vol. 60, No. 3Production and Quality Control of Adenoviral Vectors for Clinical TrialsJournal of Bacteriology and Virology, Vol. 38, No. 4Silver Spoons and Golden Genes: Genetic Engineering and the Egalitarian Ethos21 June 2016 | American Journal of Law & Medicine, Vol. 33, No. 4Integration of plasmid DNA purification and molecular therapy agent preparation using aqueous two-phase systemsJournal of Biotechnology, Vol. 131, No. 2Preparing for Our Enhanced Future5 February 2021 | Journal of Medical Regulation, Vol. 93, No. 2Adenoviral vectors for gene therapy17 April 2007 | Molecular Biotechnology, Vol. 36, No. 1Gene Therapy Clinical Studies And The CONSORT Guidelines4 April 2007 | Human Gene Therapy, Vol. 0, No. 0Long-Term Toxicity Studies in Canine of E10A, An Adenoviral Vector for Human Endostatin Gene Bi-Jun Huang, Ran-Yi Liu, Jia-Ling Huang, Zhi-Hui Liang, George Fu Gao, Jiang-Xue Wu, and Wenlin Huang5 April 2007 | Human Gene Therapy, Vol. 18, No. 3Casting light on molecular events underlying anti-cancer drug treatment: What can be seen from the proteomics point of view?Cancer Treatment Reviews, Vol. 32, No. 8Cell Biological and Biophysical Aspects of Lipid-mediated Gene Delivery26 October 2006 | Bioscience Reports, Vol. 26, No. 4Regulation of Gene Therapy in China James M. Wilson10 October 2006 | Human Gene Therapy, Vol. 17, No. 10Regulation of Gene Therapy in China7 September 2006 | Human Gene Therapy, Vol. 0, No. 0Biopharmaceutical benchmarks 20061 July 2006 | Nature Biotechnology, Vol. 24, No. 7Front Matter28 February 2013Preparation of gene-viral therapeutic system CNHK200-hA and its antitumor activity on lung cancerChinese Journal of Cancer Research, Vol. 18, No. 1Plasmid Vaccines and Therapeutics: From Design to Applications8 November 2005Market Development of Biopharmaceuticals Volume 16Issue 9Sep 2005 InformationCopyright 2005, Mary Ann Liebert, Inc.To cite this article:James M. Wilson.Gendicine: The First Commercial Gene Therapy Product; Chinese Translation of Editorial.Human Gene Therapy.Sep 2005.1014-1015.http://doi.org/10.1089/hum.2005.16.1014Published in Volume: 16 Issue 9: September 8, 2005PDF download
Referência(s)